$7.96
Insights on Vir Biotechnology Inc
Revenue is up for the last 3 quarters, -12.72M → 16.78M (in $), with an average increase of 167.4% per quarter
Netprofit is up for the last 3 quarters, -194.77M → -115.97M (in $), with an average increase of 30.1% per quarter
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 113.7%
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 327.3%
0.0%
Downside
Day's Volatility :3.98%
Upside
3.98%
3.02%
Downside
52 Weeks Volatility :71.91%
Upside
71.03%
Period | Vir Biotechnology Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.73% | -0.7% | 0.0% |
6 Months | -1.55% | 6.6% | 0.0% |
1 Year | -67.0% | 3.7% | -1.5% |
3 Years | -82.53% | 14.0% | -21.8% |
Market Capitalization | 1.1B |
Book Value | $11.8 |
Earnings Per Share (EPS) | -4.59 |
Wall Street Target Price | 32.29 |
Profit Margin | 0.0% |
Operating Margin TTM | -724.57% |
Return On Assets TTM | -17.48% |
Return On Equity TTM | -33.54% |
Revenue TTM | 86.2M |
Revenue Per Share TTM | 0.64 |
Quarterly Revenue Growth YOY | -66.0% |
Gross Profit TTM | 1.0B |
EBITDA | -640.6M |
Diluted Eps TTM | -4.59 |
Quarterly Earnings Growth YOY | 0.59 |
EPS Estimate Current Year | -4.09 |
EPS Estimate Next Year | -3.98 |
EPS Estimate Current Quarter | -1.01 |
EPS Estimate Next Quarter | -1.11 |
What analysts predicted
Upside of 305.65%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 868.0K | ↑ 482.55% |
Net Income | -115.9M | ↑ 65.9% |
Net Profit Margin | -13.4K% | ↑ 33529.85% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 711.0K | ↓ 18.09% |
Net Income | -174.7M | ↑ 50.74% |
Net Profit Margin | -24.6K% | ↓ 11217.95% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 76.4M | ↑ 10640.93% |
Net Income | -298.7M | ↑ 70.98% |
Net Profit Margin | -391.09% | ↑ 24177.55% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 1323.46% |
Net Income | 528.6M | ↓ 276.98% |
Net Profit Margin | 48.62% | ↑ 439.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↑ 45.39% |
Net Income | 515.8M | ↓ 2.41% |
Net Profit Margin | 32.64% | ↓ 15.98% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 86.2M | ↓ 94.55% |
Net Income | -615.1M | ↓ 219.24% |
Net Profit Margin | -713.69% | ↓ 746.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 371.4M | ↓ 970.13% |
Net Income | 175.3M | ↓ 329.19% |
Net Profit Margin | 47.2% | ↓ 132.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 21.8M | ↓ 94.13% |
Net Income | -101.6M | ↓ 157.96% |
Net Profit Margin | -466.3% | ↓ 513.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.7M | ↑ 114.38% |
Net Income | -141.0M | ↑ 38.73% |
Net Profit Margin | -301.76% | ↑ 164.54% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | -12.7M | ↓ 127.23% |
Net Income | -194.8M | ↑ 38.18% |
Net Profit Margin | 1.5K% | ↑ 1832.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | -4.1M | ↓ 67.79% |
Net Income | -163.4M | ↓ 16.1% |
Net Profit Margin | 4.0K% | ↑ 2456.62% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.8M | ↓ 509.64% |
Net Income | -116.0M | ↓ 29.03% |
Net Profit Margin | -690.85% | ↓ 4678.48% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 191.6M | ↓ 23.84% |
Total Liabilities | 370.8M | ↑ 15.69% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 512.1M | ↑ 167.27% |
Total Liabilities | 88.1M | ↓ 76.23% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 918.8M | ↑ 79.42% |
Total Liabilities | 201.9M | ↑ 129.11% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 112.71% |
Total Liabilities | 522.4M | ↑ 158.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 43.38% |
Total Liabilities | 724.1M | ↑ 38.61% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↓ 30.05% |
Total Liabilities | 369.9M | ↓ 48.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↑ 2.94% |
Total Liabilities | 546.1M | ↓ 18.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↑ 3.94% |
Total Liabilities | 724.1M | ↑ 32.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↓ 4.86% |
Total Liabilities | 695.1M | ↓ 4.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 15.83% |
Total Liabilities | 433.7M | ↓ 37.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 8.87% |
Total Liabilities | 369.8M | ↓ 14.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 4.15% |
Total Liabilities | 369.9M | ↑ 0.01% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -94.1M | ↑ 41.75% |
Investing Cash Flow | -60.4M | ↑ 101.51% |
Financing Cash Flow | 25.0M | ↓ 90.79% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -129.6M | ↑ 37.77% |
Investing Cash Flow | -256.2M | ↑ 323.81% |
Financing Cash Flow | 449.2M | ↑ 1698.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -190.9M | ↑ 47.29% |
Investing Cash Flow | -9.9M | ↓ 96.15% |
Financing Cash Flow | 529.5M | ↑ 17.86% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.6M | ↓ 75.08% |
Investing Cash Flow | -140.8M | ↑ 1327.84% |
Financing Cash Flow | 100.3M | ↓ 81.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↓ 3595.04% |
Investing Cash Flow | -1.2B | ↑ 747.54% |
Financing Cash Flow | 34.8M | ↓ 65.35% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 117.9M | ↓ 87.72% |
Investing Cash Flow | -662.6M | ↑ 143.31% |
Financing Cash Flow | 2.0M | ↓ 35.55% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 35.1M | ↓ 70.21% |
Investing Cash Flow | -153.1M | ↓ 76.89% |
Financing Cash Flow | 2.0M | ↑ 1.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -125.8M | ↓ 458.09% |
Investing Cash Flow | 98.1M | ↓ 164.05% |
Financing Cash Flow | 2.3M | ↑ 16.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -389.2M | ↑ 209.46% |
Investing Cash Flow | 230.3M | ↑ 134.83% |
Financing Cash Flow | 3.2M | ↑ 35.62% |
Sell
Neutral
Buy
Vir Biotechnology Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Vir Biotechnology Inc | -22.75% | -1.55% | -67.0% | -82.53% | -41.16% |
Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Vir Biotechnology Inc | 6.4 | NA | NA | -4.09 | -0.34 | -0.17 | NA | 11.8 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Vir Biotechnology Inc | Buy | $1.1B | -41.16% | 6.4 | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
BlackRock Inc
SB INVESTMENT ADVISERS (UK) LTD
Vanguard Group Inc
State Street Corporation
Baillie Gifford & Co Limited.
AllianceBernstein L.P.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Organization | Vir Biotechnology Inc |
Employees | 587 |
CEO | Dr. Ann M. Hanly Ph.D. |
Industry | Commercial Services |